For US Consumers
ONCASPAR (pegaspargase) is part of a chemotherapy program used to treat patients who have acute lymphoblastic leukemia (ALL), a type of blood cancer that affects the white blood cells that help fight infection. ONCASPAR is also used in patients who have had an allergic reaction to a different type of asparaginase treatment.
 
Important Safety Information
ONCASPAR® should not be given to people who have had:
  • History of serious allergic reactions to ONCASPAR
  • History of serious blood clots with prior L-asparaginase therapy
  • History of swelling of the pancreas and/or stomach pain with prior L-asparaginase therapy
  • History of serious bleeding events with prior L-asparaginase therapy

See Full Important Safety Information

If you or someone you care for has acute lymphoblastic leukemia (ALL), you may be looking for resources that may be helpful during the course of treatment.

Through ONE for ALL, you'll have access to information that can help you better understand certain aspects of treatment and a few tools and tips designed to make the process a little easier.

If you have any questions, please call:
US toll-free: 1-888-229-8379; Option 4 
Puerto Rico toll-free: 1-844-229-7575?
Always talk with your healthcare team and ask questions. They are your best source of information about ALL and the treatment you or your child is receiving.
Indication and Important Safety Information

What is ONCASPAR?
ONCASPAR (pegaspargase) is part of a chemotherapy program used to treat patients who have acute lymphoblastic leukemia (ALL), a type of blood cancer that affects the white blood cells that help fight infection. ONCASPAR is also used in patients who have had an allergic reaction to a different type of asparaginase treatment.

How is ONCASPAR given?
ONCASPAR is given as an injection (a shot) into a muscle or infusion into a vein.

Important Risk Information
Who should not receive ONCASPAR?
ONCASPAR should not be given to people who have had:

  • History of serious allergic reactions to ONCASPAR
  • History of serious blood clots with prior L-asparaginase therapy
  • History of swelling of the pancreas and/or stomach pain with prior L-asparaginase therapy
  • History of serious bleeding events with prior L-asparaginase therapy

What are the possible side effects of ONCASPAR?
ONCASPAR may cause serious side effects. Call your healthcare professional or go to your emergency department right away if you get:

  • Hives, swelling in the mouth or throat, itching, trouble breathing, wheezing, fainting or dizziness. These could be signs of a serious allergic reaction.
  • Severe headache, arm or leg swelling, acute shortness of breath, or chest pain. These could be signs of a blood clot.
  • Stomach pain that may radiate to your back, nausea and vomiting. These could be signs of a serious pancreas problem.
  • Feeling very thirsty, dry mouth and frequent need to urinate. These may be signs of too much sugar in the blood or glucose intolerance.
  • Excessive bleeding may be a sign of impaired blood clotting.
  • Dark-colored urine or yellowing of skin or eyes. These could be signs of a liver problem.

What are the most common side effects with ONCASPAR?

  • Allergic reactions
  • Too much sugar in the blood
  • Swelling of the pancreas
  • Blood clots
  • Bleeding
  • Liver problems

These are not all the possible side effects with ONCASPAR. Talk to your healthcare professional about any side effects that bother you or that don’t go away.
You are encouraged to report suspected side effects by contacting FDA at 1-800-FDA-1088 or www.fda.gov/medwatch or Shire at 1-800-999-1785.
For additional safety information, click here for Full Prescribing Information and discuss with your doctor.

All content on this website, including text, images, graphics, sound files, and their arrangement, is copyrighted and owned by Shire and is protected by international copyright laws. All other intellectual property rights are reserved. The content may not be copied for commercial use or distribution, nor may these objects be downloaded, modified, or posted to other sites.

This site is intended solely for US residents and is governed solely by US laws and government regulations. Please see our Legal Notice for more information. While Shire US Inc. makes reasonable efforts to include accurate, up-to-date information on this site, Shire US Inc. makes no warranties or representations as to its accuracy. Shire US Inc. assumes no liability for any errors or omissions in the content of this site.

The information on this site is not intended to make a diagnosis or to take the place of talking to a US health care professional.

Shire Logo

Privacy NoticeLegal DisclaimersContact Us

© 2018 Shire US Inc., Lexington, MA 02421. All rights reserved. 1-800-828-2088 SHIRE and the Shire Logo are registered trademarks of Shire Pharmaceutical Holdings Ireland Limited or its affiliates. ONCASPAR is a registered trademark of Baxalta Incorporated, a wholly owned, indirect subsidiary of Shire plc. All other product brands or trademarks that may appear herein are the property of their respective owners.
S34211 07/18 
Navigation
ONCASPAR Logo
For US Consumers

ONCASPAR (pegaspargase) is part of a chemotherapy program used to treat patients who have acute lymphoblastic leukemia (ALL), a type of blood cancer that affects the white blood cells that help fight infection. ONCASPAR is also used in patients who have had an allergic reaction to a different type of asparaginase treatment.

Important Safety Information
ONCASPAR® should not be given to people who have had:
  • History of serious allergic reactions to ONCASPAR
  • History of serious blood clots with prior L-asparaginase therapy
  • History of swelling of the pancreas and/or stomach pain with prior L-asparaginase therapy
  • History of serious bleeding events with prior L-asparaginase therapy
See Full Important Safety Information
If you have any questions, please call:
US toll-free: 1-888-229-8379; Option 4 Puerto Rico toll-free: 1-844-229-7575 Always talk with your healthcare team and ask questions. They are your best source of information about ALL and the treatment you or your child is receiving.
Indication and Important Safety Information

What is ONCASPAR?
ONCASPAR (pegaspargase)
is part of a chemotherapy program used to treat patients who have acute lymphoblastic leukemia (ALL), a type of blood cancer that affects the white blood cells that help fight infection. ONCASPAR is also used in patients who have had an allergic reaction to a different type of asparaginase treatment.

How is ONCASPAR given?
ONCASPAR is given as an injection (a shot) into a muscle or infusion into a vein.

Important Risk Information
Who should not receive ONCASPAR?
ONCASPAR should not be given to people who have had:

What are the possible side effects of ONCASPAR?
ONCASPAR may cause serious side effects. Call your healthcare professional or go to your emergency department right away if you get:

What are the most common side effects with ONCASPAR?

These are not all the possible side effects with ONCASPAR. Talk to your healthcare professional about any side effects that bother you or that don’t go away.
You are encouraged to report suspected side effects by contacting FDA at 1-800-FDA-1088 or www.fda.gov/medwatch or Shire at 1-800-999-1785.
For additional safety information, click here for Full Prescribing Information and discuss with your doctor.

All content on this website, including text, images, graphics, sound files, and their arrangement, is copyrighted and owned by Shire and is protected by international copyright laws. All other intellectual property rights are reserved. The content may not be copied for commercial use or distribution, nor may these objects be downloaded, modified, or posted to other sites.

This site is intended solely for US residents and is governed solely by US laws and government regulations. Please see our Legal Notice for more information. While Shire US Inc. makes reasonable efforts to include accurate, up-to-date information on this site, Shire US Inc. makes no warranties or representations as to its accuracy. Shire US Inc. assumes no liability for any errors or omissions in the content of this site.

The information on this site is not intended to make a diagnosis or to take the place of talking to a US health care professional.

Shire Logo
Privacy Notice
Legal Disclaimers
Contact Us

© 2018 Shire US Inc., Lexington, MA 02421. All rights reserved. 1-800-828-2088 SHIRE and the Shire Logo are registered trademarks of Shire Pharmaceutical Holdings Ireland Limited or its affiliates. ONCASPAR is a registered trademark of Baxalta Incorporated, a wholly owned, indirect subsidiary of Shire plc. All other product brands or trademarks that may appear herein are the property of their respective owners.
S34211 07/18